Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Management of CRS and ICANS after CAR-T therapy for ALL

Vipul Sheth • 13 Jul 2021
EHA 2021
Acute Lymphoblastic Leukemia Leukemia CAR-T Dexamethasone

Vipul Sheth, PhD, Fred Hutchinson Cancer Research Center, Seattle, USA, comments on the management of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) after chimeric-antigen receptor T-cell (CAR-T) therapy for patients with acute lymphoblastic leukemia (ALL). This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Vipul Sheth

T-cell lineage mixed chimerism as a prognostic factor in acute leukemia & MDS after allo-HSCT
1:52
T-cell lineage mixed chimerism as a prognostic factor in acute leukemia & MDS after allo-HSCT
Vipul Sheth • 28 Jun 2021

Related Videos

Is there a role for CAR T-cell therapy in the treatment pathway for CLL?
1:21
Is there a role for CAR T-cell therapy in the treatment pathway for CLL?
Marco Ruella • 16 Oct 2026
Access challenges to diagnosis and treatment for patients with CLL in resource-restricted countries
1:45
Access challenges to diagnosis and treatment for patients with CLL in resource-restricted countries
Celso Arrais • 17 Oct 2026
Insights into the current CLL treatment algorithm and emerging research directions
1:51
Insights into the current CLL treatment algorithm and emerging research directions
Matthew Davids • 17 Oct 2026
How has the harmonization of genomic profiling in Sweden impacted patient access to CLL diagnostics?
1:21
How has the harmonization of genomic profiling in Sweden impacted patient access to CLL diagnostics?
Richard Rosenquist • 17 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals